135 related articles for article (PubMed ID: 28509395)
21. Aggressive treatment for postcardiac transplant lymphoproliferation.
Swinnen LJ; Mullen GM; Carr TJ; Costanzo MR; Fisher RI
Blood; 1995 Nov; 86(9):3333-40. PubMed ID: 7579436
[TBL] [Abstract][Full Text] [Related]
22. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
23. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
24. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
25. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy.
Garrett TJ; Chadburn A; Barr ML; Drusin RE; Chen JM; Schulman LL; Smith CR; Reison DS; Rose EA; Michler RE
Cancer; 1993 Nov; 72(9):2782-5. PubMed ID: 8402504
[TBL] [Abstract][Full Text] [Related]
26. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).
García-Cadenas I; Yáñez L; Jarque I; Martino R; Pérez-Simón JA; Valcárcel D; Sanz J; Bermúdez A; Muñoz C; Calderón-Cabrera C; García E; Alonso L; Suárez-Lledó M; González Vicent M; Heras I; Viguria MC; Batlle M; Vázquez L; López J; Solano C;
Eur J Haematol; 2019 Jun; 102(6):465-471. PubMed ID: 30828868
[TBL] [Abstract][Full Text] [Related]
27. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
28. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
29. Post-Transplant Lymphoproliferative Disorder (PTLD) Manifesting in the Oral Cavity of a 13-Year-Old Liver Transplant Recipient (LTx).
Krasuska-Sławińska E; Minko-Chojnowska I; Pawłowska J; Dembowska-Bagińska B; Pronicki M; Olczak-Kowalczyk D
Ann Transplant; 2015 Aug; 20():478-82. PubMed ID: 26285106
[TBL] [Abstract][Full Text] [Related]
30. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment.
Chan TS; Hwang YY; Gill H; Au WY; Leung AY; Tse E; Chim CS; Loong F; Kwong YL
Clin Transplant; 2012; 26(5):679-83. PubMed ID: 22324300
[TBL] [Abstract][Full Text] [Related]
31. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
32. Long-term remission in an adult heart transplant recipient with advanced Burkitt's lymphoma post-transplant lymphoproliferative disorder after anthracycline-free chemotherapy: A case report and literature review.
AbdelHameid D; Felice A; Cooper LB; Katugaha SB
Transpl Infect Dis; 2020 Aug; 22(4):e13265. PubMed ID: 32077552
[TBL] [Abstract][Full Text] [Related]
33. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
34. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
Orjuela M; Gross TG; Cheung YK; Alobeid B; Morris E; Cairo MS
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
[TBL] [Abstract][Full Text] [Related]
36. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants.
Davis CL; Wood BL; Sabath DE; Joseph JS; Stehman-Breen C; Broudy VC
Transplantation; 1998 Dec; 66(12):1770-9. PubMed ID: 9884275
[TBL] [Abstract][Full Text] [Related]
37. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.
Gupta S; Fricker FJ; González-Peralta RP; Slayton WB; Schuler PM; Dharnidharka VR
Pediatr Transplant; 2010 Nov; 14(7):896-902. PubMed ID: 20642490
[TBL] [Abstract][Full Text] [Related]
38. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
39. PTLD treatment: a step forward, a long way to go.
Montserrat E
Lancet Oncol; 2012 Feb; 13(2):120-1. PubMed ID: 22173061
[No Abstract] [Full Text] [Related]
40. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas.
Weis TM; Marini BL; Nachar VR; Brown AM; Phillips TJ; Brown J; Wilcox RA; Kaminski MS; Devata S; Perissinotti AJ
Leuk Lymphoma; 2020 May; 61(5):1126-1132. PubMed ID: 31876206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
